Table 1.

Clinical Characteristics of the Original and Validation Cohorts.

Characteristic	CFL-1 Expression		P value
	High	Low
Testing Cohort (n = 111)	55 (49%)	56 (51%)
Age (years)	64.6 ± 9.6	64.9 ± 9.7	0.842
Gender
Male	30 (54%)	33 (59%)	0.784
Female	25 (46%)	23 (41%)
Tumor type
Adenocarcinoma	28 (51%)	30 (54%)	0.928
Squamous-cell	27 (49%)	26 (46%)
Tumor TNM Stage
Ia	20 (36%)	20 (36%)	0.999
Ib	13 (24%)	14 (25%)
II	9 (16%)	9 (16%)
III–IV	13 (24%)	13 (23%)
Validation Cohort (n = 86)	43 (50%)	43 (50%)
Age (years)	62.3 ± 8.8	65.1 ± 10.7	0.187
Gender
Male	21 (49%)	14 (33%)	0.198
Female	22 (51%)	29 (67%)
Tumor type/differentiation
Adenocarcinoma/well	12 (28%)	12 (28%)	0.964
Adenocarcinoma/ moderate	21 (49%)	20 (47%)
Adenocarcinoma/ poor	10 (23%)	11 (26%)
Tumor TNM Stage
I	34 (79%)	33 (77%)	0.999
III	9 (21%)	10 (23%)